Doyle Wealth Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-2,856
Closed -$220K 193
2020
Q2
$220K Sell
2,856
-958
-25% -$73.4K 0.03% 166
2020
Q1
$285K Buy
3,814
+388
+11% +$26.8K 0.05% 139
2019
Q4
$223K Sell
3,426
-142,686
-98% -$9.29M 0.03% 195
2019
Q3
$9.26M Sell
146,112
-3,131
-2% -$205K 1.28% 36
2019
Q2
$10.1M Sell
149,243
-1,092
-0.7% -$71.8K 1.39% 32
2019
Q1
$9.86M Sell
150,335
-1,409
-0.9% -$93.6K 1.43% 33
2018
Q4
$9.49M Sell
151,744
-8,011
-5% -$560K 1.6% 24
2018
Q3
$12.3M Buy
159,755
+2,529
+2% +$191K 1.92% 17
2018
Q2
$11.1M Buy
157,226
+5,829
+4% +$412K 1.84% 20
2018
Q1
$11.4M Buy
151,397
+6,199
+4% +$493K 1.92% 21
2017
Q4
$10.4M Sell
145,198
-2,193
-1% -$167K 1.76% 22
2017
Q3
$11.9M Buy
147,391
+8,178
+6% +$625K 2.09% 18
2017
Q2
$9.85M Buy
139,213
+19,463
+16% +$1.3M 1.83% 22
2017
Q1
$8.13M Buy
+119,750
New +$8.42M 1.66% 20

Other funds holding GILD

Doyle Wealth Management's GILD Position: Q3 2020 in Review

Doyle Wealth Management sold out of Gilead Sciences (GILD) in Q3 2020, closing a stake of 2,856 shares — an estimated $220K sold.

Doyle Wealth Management first reported a position in GILD in Q1 2017 and held it in 14 quarters. The position peaked at $12.3M in Q3 2018. 1,538 funds tracked by Wall St. Rank hold GILD as of Q3 2020.

  • Doyle Wealth Management reported no remaining Gilead Sciences position as of Q3 2020 after selling out during the quarter.
  • Doyle Wealth Management sold 2,856 Gilead Sciences shares in Q3 2020, an estimated $220K.
  • Doyle Wealth Management first reported a position in Gilead Sciences in Q1 2017 and held it in 14 quarters.
  • Doyle Wealth Management's Gilead Sciences position peaked at $12.3M in Q3 2018.
  • 1,538 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2020.

Based on Doyle Wealth Management's 13F filing for Q3 2020, filed 13 Nov 2020.